Quoin Pharmaceuticals, Ltd. (QNRX) Stock Price & Analysis
Quoin Pharmaceuticals, Ltd. (QNRX) fell 2.06% to USD 4.28 as of July 25, 2026 at 04:29 UTC, according to Nexqual real-time market data.
QNRX last closed at USD 4.37; the session ranged USD 4.2–4.29 on volume of 4,657 shares. Market capitalization is $8.60M, with a 52-week range of USD 3.25–41.8 (NCM). Source: Nexqual, July 25, 2026 at 04:29 UTC.
Key Statistics (as of July 25, 2026 at 04:29 UTC)
| Price | USD 4.28 |
|---|---|
| Change | ▼ 2.06% (down) |
| Previous Close | USD 4.37 |
| Open | USD 4.25 |
| Day Range | USD 4.2 – 4.29 |
| 52-Week Range | USD 3.25 – 41.8 |
| Volume | 4,657 shares |
| Market Cap | $8.60M |
| Exchange | NCM |
Technical Analysis (QNRX)
Nexqual's technical model rates QNRX "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:29 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.76 (neutral) |
| vs SMA50 | Below (USD 4.64) |
| MACD | -0.11 (negative) |
Analyst Ratings (QNRX)
Wall Street analysts rate QNRX "Strong Buy" based on 5 analysts, with a mean price target of USD 21.4 (range USD 12–35), per Nexqual as of July 25, 2026 at 04:29 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 21.4 |
| High Target | USD 35 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (QNRX)
| EPS Estimate | USD -1.77 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.77 vs est -2.26 ▲ beat |
| 2025-12-31 | USD -1.74 vs est -4.02 ▲ beat |
| 2025-09-30 | USD -6.7 vs est -1.92 ▼ miss |
| 2025-06-30 | USD -6.27 vs est -4.55 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:29 UTC.
Financials & Fundamentals (QNRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -231.18% |
| Debt / Equity | 24.78 |
| Current Ratio | 2.87 |
| Total Cash | $14.04M |
| Total Debt | $2.17M |
| Free Cash Flow | $-9.44M |
Source: Nexqual, July 25, 2026 at 04:29 UTC.
Financial Health Score (QNRX)
Nexqual rates Quoin Pharmaceuticals, Ltd.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$16M |
| Efficiency | Critical — ROE -231%, ROA -76.2% |
Ownership (QNRX)
| Insider Ownership | +2.63% |
|---|---|
| Institutional Ownership | +52.52% |
| Shares Outstanding | 2.01M |
| Float | 1.63M |
| Short % of Float | +13.09% |
Source: Nexqual, July 25, 2026 at 04:29 UTC.
Leadership (QNRX)
Quoin Pharmaceuticals, Ltd. is led by Michael Myers (age 63), Co-Founder, CEO & Chairman, per Nexqual as of July 25, 2026 at 04:29 UTC.
| Co-Founder, CEO & Chairman | Michael Myers (age 63) |
|---|---|
| Co-Founder, COO & Director | Denise Carter (age 56) |
| Chief Financial Officer | Sally Lawlor (age 42) |
Major Backers & Investors (QNRX)
Notable institutional backers of Quoin Pharmaceuticals, Ltd. include Ikarian Capital, LLC, Dauntless Investment Group, LLC , Summittx Capital, L.P., according to Nexqual as of July 25, 2026 at 04:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 10.53% |
| Dauntless Investment Group, LLC | 9.79% |
| Summittx Capital, L.P. | 4.99% |
| Velan Capital Investment Management LP | 4.22% |
| Woodline Partners LP | 3.96% |
| Millennium Management | 3.8% |
| Aberdeen Group plc | 3.73% |
| Soleus Capital Management, L.P. | 3.62% |
Source: Nexqual, July 25, 2026 at 04:29 UTC.
From Quoin Pharmaceuticals, Ltd.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
- The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
- It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases.
- It has a research agreement with Queensland University of Technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REVB | Revelation Biosciences, Inc. | USD 1.06 | ▼ 7.83% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| VRAX | Virax Biolabs Group Limited | USD 3.19 | ▼ 12.36% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▲ 0.79% |
| ILAG | Intelligent Living Application | USD 3.45 | ▼ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:29 UTC. This page is informational and not investment advice.